HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $20 to $18.

Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stock in a registered direct offering for aggregate gross proceeds of approximately $100 million. The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset

ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments. ENTR-601-44 demonstrated significant plasma concentration, muscle concentration and exon skipping, at levels that suggest the potential for a clinically meaningful starting dose in planned upcoming patient trials. Phase 2 planning underway for separate ENTR-601-44 and ENTR-601-45 clinical trials with regulatory filings anticipated in Q4 2024

Gainers Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82% to $1.93. The company's market cap stands at $47.8 million. Lyell Immunopharma (NASDAQ:LYEL) stock rose 7.5% to $2.86. The market value of their outstanding shares is at $726.5 million. iSpecimen (NASDAQ:ISPC) shares rose 6.38% to $0.24. The market value of their outstanding shares is at $2.1 million. Akanda (NASDAQ:AKAN) shares moved upwards by 5.89% to $0.16. The company's market cap stands at $1.9 million. Bright Green (NASDAQ:BGXX) shares moved upwards by 5.0% to $0.25. The market val

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. HCI Group The Trade: HCI Group Inc (NYSE:HCI) CEO Paresh Patel acquired a total of 1,000 shares an average price of $114.90

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Cardlytics The Trade: Cardlytics, Inc. (NASDAQ:CDLX) 10% owner Clifford Sosin acquired a total of 350,000 shares an average

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $20 price target.

Entrada Therapeutics (NASDAQ:TRDA) reported its Q4 earnings results on Wednesday, March 13, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Entrada Therapeutics missed estimated earnings by -71.0%, reporting an EPS of $-0.29 versus an estimate of $-0.17. Revenue was up $41.85 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $1.76 which was followed by a 1.0% drop in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for Entrada Therapeutics visit their earnings calendar here. This article was generated by Benzinga's au

10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

144 - Entrada Therapeutics, Inc. (0001689375) (Subject)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

424B5 - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

144 - Entrada Therapeutics, Inc. (0001689375) (Subject)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clinical trials for both ENTR-601-44 and ENTR-601-45 in Q4 2024 – – Vertex announced the completion of the single ascending dose (SAD) and the initiation of the multiple ascending dose (MAD) portions of global Phase 1/2 clinical trial for partnered program VX-670 in people with DM1 – – Cash runway expected into 2027 with $449 million in cash, cash equivalents and marketable securities as of September 30, 2024 – BOSTON, Nov. 05, 2024 (GLOBE NEWS

– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented for the first time, showing exon skipping and dystrophin production for ENTR-601-45, supports the planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 clinical trial – BOSTON, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets lo

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately. "Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company's diverse pipeline of proprietary intracellular therapeutics," said Dipal Doshi, Chief Ex

āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced the recipients of its second annua

– Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent plasma and muscle concentration, and exon skipping – – Planning underway for separate global Phase 2 clinical trials for ENTR-601-44 and ENTR-601-45 with regulatory filings anticipated in Q4 2024 – – Completed $100 million registered direct offering led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – Cash runway expected into 2027 with $470 million in cash, cash equivalents, and marketable securities as of June 30, 2024 – BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASD

BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stock in a registered direct offering for aggregate gross proceeds of approximately $100 million. The offering was led by a U.S.-based healthcare focused investor, two global mutual funds a

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company's website at www.entradatx.com. A replay will be available on the Entrad

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York, NY. The fireside chat will be held on Monday, May 20, 2024, at 9:30 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company's website at www.entradatx.com. A replay will be availab

– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement of its Phase 1/2 clinical trial of VX-670 for DM1 – – Cash runway expected through the second quarter of 2026 with $327 million in cash, cash equivalents and marketable securities as of March 31, 2024 – BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellul

āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates. "In the first quarter, we successfully closed on our transformational collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1, the most prev

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt "Bernie" Zeiher to its Board of Directors, effective immediately. Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma. "Bernie is a dynamic life sciences leader and we look forward to having him join our Board of Directors," said Dipal Doshi, President and Chief Executive Officer of Entrada. "As the former Chief Medical Officer and President of Development at

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald previously served as Entrada's Vice President of Corporate Communications and Investor Relations. She remains a member of the Entrada executive team and will report to Dipal Doshi, Entrada's President and Chief Executive Officer. "Karla is a transformational leader who has already demonstrated her value as a membe

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)